FDG PET-CT in rheumatological diseases.
Manil SubesingheShaheel BhuvaNikita ArumallaAndrew CopeDavid D'CruzSujith SubesinghePublished in: Rheumatology (Oxford, England) (2021)
2-deoxy-2[18F]fluoro-D-glucose (FDG) positron emission tomography-computed tomography (PET-CT) has revolutionised oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT, also occur in a wide range of inflammatory cells; exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wide range of infective and inflammatory diseases. Rheumatological diseases can affect multiple sites within the musculoskeletal system alongside multi-organ extra-articular disease manifestations. Inflammation is central to these diseases, making FDG PET-CT a logical choice. In this review article, we will describe the various applications of FDG PET-CT in rheumatological diseases using illustrative examples to highlight the beneficial role of FDG PET-CT in each case.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- oxidative stress
- pet imaging
- magnetic resonance imaging
- induced apoptosis
- type diabetes
- high resolution
- rectal cancer
- adipose tissue
- magnetic resonance
- blood pressure
- cell proliferation
- blood glucose
- skeletal muscle
- insulin resistance
- contrast enhanced
- radical prostatectomy
- minimally invasive